Awardee OrganizationVIRGINIA COMMONWEALTH UNIVERSITY
Description
Abstract Text
Project Summary/Abstract
Biliary atresia (BA) is an important and perplexing disease of neonates that has eluded major
discoveries of etiology and pathophysiology for decades. Recently, the NIDDK-supported
ChiLDReN network performed exome sequencing on a subset of BA individuals with cardiac and
abdominal laterality features–those with the BA Splenic Malformation (BASM) syndrome in order
to determine if there is a genetic etiology in this group with multi-organ developmental
dysmorphogenesis. Analysis of BASM exome sequences found several participants with
significant mutations in the ciliary gene PKD1L1, a gene associated with cardiac laterality defects,
but not yet linked to biliary tract disease. In order to explore mechanistic consequences to
impaired PKD1L1 signaling in humans, we developed an intrahepatic cholangiocyte-restricted
Pkd1l1Fl/Fl;Afp-Cre (LKO) mouse. Preliminary data indicates that absence of Pkd1l1 in the
developing mouse liver leads not only to early biliary dysmorphology, but an enhanced peribiliary
fibroinflammation at adult ages, moreso in the setting of distal obstruction after bile duct ligation
(BDL). These histologic features strongly mimic those seen in human BA livers. Aim 1 explores
the fibroinflammatory consequences of absent Pkd1l1 signaling in the LKO and other informative
Pkd1l1Fl/Fl cross-bred lines (including one with a human bile acid pool and another that will delete
Pkd1l1 in the entire biliary tree) and response to select bile acid based therapeutic interventions.
Aim 2 explores the delineation of early bile duct dysmorphology in developing prenatal and early
postnatal livers with lineage tracing and multiplexed spatial RNA studies. Finally, Aim 3 is an in
vitro set of experiments with cholangiocyte organoids, polarized Transwell cultures and 3d duct-
on-a-chip studies to define the molecular and signaling consequences in isolated Pkd1l1Fl/Fl and
LKO cholangiocytes. Taken together we anticipate that these 3 Aims will provide first-ever genetic
models of BA poised to discover new cellular and molecular mechanisms of biliary tract reactivity
and damage. In addition, testing of bile acid pathway-based agents in informative Pkd1l1 mouse
models may help provide supportive pre-clinical evidence to address the current paucity of
effective medical therapeutics in BA.
Public Health Relevance Statement
Project Narrative
Biliary atresia the principal reason for liver transplantation in children, yet is without known
causes or effective medical therapies. The research in this proposal aims to fill these large
knowledge gaps by performing studies in a newly-created mouse model of biliary atresia. This
novel mouse model is based upon recent genetic studies indicating that mutations in the gene
PKD1L1 may be a cause of biliary atresia.
NIH Spending Category
No NIH Spending Category available.
Project Terms
3-DimensionalAbdomenAddressAdultAgeAgonistAntibodiesApicalBile AcidsBile fluidBiliaryBiliary AtresiaBiliary Tract DiseasesBiologyCardiacCell PhysiologyCellsChemistryChildChild SupportCholestasisCiliaClinicalComparative StudyCrossbreedingDataDefectDevelopmentDiseaseDistalDuct (organ) structureDysmorphologyEtiologyEvaluationExposure toExtrahepatic Bile DuctsFunctional disorderGenerationsGenesGenetic ModelsGenetic Predisposition to DiseaseGenetic studyHandednessHistologicHistologyHumanHuman GeneticsImpairmentIn VitroIndividualKnowledgeLigationLinkLiverMedicalMembraneMembrane ProteinsModelingMolecularMusMutationN-terminalNational Institute of Diabetes and Digestive and Kidney DiseasesObstructionOrganOrganoidsOryctolagus cuniculusParticipantPathogenesisPathway interactionsPolycystic Kidney DiseasesProteomicsRNAResearchRoleSerumSignal TransductionSubcellular structureSurfaceSyndromeTestingTherapeuticTherapeutic InterventionTimeTransgenic OrganismsTreatment EfficacyVariantbile ductbiliary tractcholangiocyteefficacy evaluationexomeexome sequencingexperimental studyhydrophilicityinhibitorinsightintrahepaticliver developmentliver transplantationmalformationmouse modelneonatenovelnovel strategiespostnatalpre-clinicalprenatalpressureresponsethree-dimensional modelingtranscriptomics
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
847
DUNS Number
105300446
UEI
MLQFL4JSSAA9
Project Start Date
15-June-2023
Project End Date
30-April-2027
Budget Start Date
01-May-2024
Budget End Date
30-April-2025
Project Funding Information for 2024
Total Funding
$601,309
Direct Costs
$413,173
Indirect Costs
$188,136
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Diabetes and Digestive and Kidney Diseases
$601,309
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 7R01DK135815-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 7R01DK135815-02
Patents
No Patents information available for 7R01DK135815-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 7R01DK135815-02
Clinical Studies
No Clinical Studies information available for 7R01DK135815-02
News and More
Related News Releases
No news release information available for 7R01DK135815-02
History
No Historical information available for 7R01DK135815-02
Similar Projects
No Similar Projects information available for 7R01DK135815-02